1
Return

Light-controlled CRISPR–dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications

delete2026-06-24
delete0
PRE
AI
N
Naiyereh Alipour Eskandani
D
Danial Mirzaee
M
Marzieh Ramezani Farani *
A
Afrooz Hatami
M
Mohsen Hatami
M
Maryam Ghasemzaei
S
Seyed Majid Ghoreishian
S
Seung-Kyu Hwang *
Y
Yun Suk Huh *
DOI：10.1016/j.addr.2026.115921delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Light-gated CRISPR–dCas9 enables locus-specific, reversible epigenome editing in cancer. • Blue-to-near-infrared optogenetic systems provide deep, multiplexed optical control. • Viral, non-viral, and smart nanocarriers are co-designed with clinical light delivery. • Opto-epigenome editors target tumor suppressors, oncogenes, stemness, and immunity. • Translational roadmaps integrate biomarkers, regulation, manufacturing, and AI-driven design.

Journal

Advanced Drug Delivery Reviews cover
Advanced Drug Delivery Reviews
IF:
17.6
Papers:
4.5K
Citations:
5.1W

Organization

S
south carolina state university
Scholars:
113
Papers: 103
Citations: 3
S
Shiraz University of Technology
Scholars:
1.7K
Papers: 1.9K
Citations: 1.6K
I
inha university
Scholars:
1.5K
Papers: 722
Citations: 0
U
university of tehran
Scholars:
1.7K
Papers: 902
Citations: 0
I
islamic azad university
Scholars:
4.0K
Papers: 2.0K
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers